Business
INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference
Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that
About this update from Inmune Bio Inc.
[{"type":"text","content":"Boca Raton, FL, Sept. 07, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness a patient’s immune system to fight disease, announced today that RJ Tesi, MD, Chief Executive Officer, and David Moss, Chief Financial Officer, will participate in two September 2023 conferences. Baird Global Healthcare Conference 2023 Fireside chat Date:September 13, 2023Time:2:00 PM ET Dr Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference. The conference is being held September 12 -13, 2023 at the InterContinental New York Barclay. To register for the conference, click here: H.C. Wainwright 25th Annual Global Investment Conference Presentation Date:September 13, 2023Time:3:30 PM ET Dr Tesi and Mr. Moss will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click here. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking sta...